重组人血管内皮抑制素联合化疗治疗晚期胃癌的价值评估

目的 探讨晚期胃癌患者接受重组人血管内皮抑制素联合化疗治疗的效果.方法 选取2012年6月至2020年6月本院收治的68例晚期胃癌患者,按照抽签的方式分为联合组和化疗组,各34例.联合组接受重组人血管内皮抑制素联合化疗治疗,化疗组接受单纯化疗治疗,比较两组临床疗效、不良反应发生率、QOL评分、Karnofsky评分、血...

Evaluation of recombinant human endostatin combined with chemotherapy in the treatment ofadvanced gastric cancer

Objective To investigate the efficacy of recombinant human angioendostatin combined with chemotherapy in patients with advanced gastric cancer. Methods 68 patients with advanced gastric cancer treated in our hospital from June 2012 to June 2020 were selected and they were divided into combined group and chemotherapy group by lottery, with 34 cases in each group. The combined group mainly received recombinant human endostatin combined with chemotherapy, while the chemotherapy group received chemotherapy alone. The clinical efficacy, incidence of adverse reactions, QOL score, Karnofsky score, serum level and immune level were compared between the two groups. Results The total effective rate in combined group was 94.12%, which was higher than 73.53% in chemotherapy group, and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups. After treatment, QOL score and Karnofsky score in combined group were higher than those in chemotherapy group, the difference was statistically significant(P<0.05). After treatment, CEA and CA199 in the combined group were lower than those in the chemotherapy group, the difference was statistically significant(P<0.05). After treatment, CD44 v6, CDl05, CD34 and CDl33 in the combined group were lower than those in the chemotherapy group, the difference was statistically significant(P<0.05). Conclusion Recombinant human endostatin combined with chemotherapy is effective in the treatment of advanced gastric cancer.